https://www.businesswire.com/news/home/20260613018476/en/Gay-Qatari-Refugee-Returns-to-Face-Qatar-at-the-World-Cup-Standing-With-Senator-Scott-Wiener-to-Say-Love-Is-Not-a-Crime 2026-06-13T17:42:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T17:42:00.000Z Gay Qatari Refugee Returns to Face Qatar at the World Cup, Standing With Senator Scott Wiener to Say Love Is Not a Crime https://mms.businesswire.com/media/20260613018476/en/2830884/21/AF-Main-Wide_JamesUpdate.jpg https://www.businesswire.com/news/home/20260610278575/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Lymphoma-DLBCL 2026-06-13T16:45:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T16:45:00.000Z Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) GMAB https://mms.businesswire.com/media/20260610278575/en/2828964/21/Genmab_Logo_Color_RGB.jpg https://www.businesswire.com/news/home/20260613021335/en/Incyte-Announces-New-Positive-Data-at-EHA-2026-Showed-INCA033989-Achieved-Rapid-Robust-and-Sustained-Clinical-and-Molecular-Responses-and-Was-Well-Tolerated-in-Patients-with-Myelofibrosis-and-Essential-Thrombocythemia 2026-06-13T15:15:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T15:15:00.000Z Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia INCY https://mms.businesswire.com/media/20260613021335/en/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260613138727/en/Dr.-Reddys-Announces-the-First-to-Market-Launch-of-Bosutinib-Tablets-400mg-a-Generic-Equivalent-of-Bosulif-in-the-United-States 2026-06-13T10:22:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T10:22:00.000Z Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States DRREDDY,500124,RDY https://mms.businesswire.com/media/20260613138727/en/2830863/21/drreddyslogo.jpg https://www.businesswire.com/news/home/20260613831839/en/Results-from-Incytes-Pivotal-Phase-3-frontMIND-Trial-of-Tafasitamab-MonjuviMinjuvi-Combination-Presented-at-the-2026-European-Hematology-Association-EHA-Congress-Plenary-Showed-Prolonged-Progression-Free-Survival 2026-06-13T10:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T10:00:00.000Z Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival INCY https://mms.businesswire.com/media/20260613831839/en/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260612564781/en/ComEd-Continues-Power-Restoration-Following-Two-Powerful-Storms 2026-06-13T01:25:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T01:25:00.000Z ComEd Continues Power Restoration Following Two Powerful Storms EXC https://mms.businesswire.com/media/20260612564781/en/1422503/21/comed_logo_sm_pos_rgb_int.jpg https://www.businesswire.com/news/home/20260612243439/en/Republic-Technologies-Inc.-Provides-Bi-Weekly-Update-On-Annual-Filings 2026-06-13T01:24:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T01:24:00.000Z Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings 7FM0,DOCKF,DOCT https://mms.businesswire.com/media/20260612243439/en/2663589/21/Republic_Technologies_Logo.jpg https://www.businesswire.com/news/home/20260612279863/en/Investor-Notice-Robbins-LLP-Informs-Investors-of-the-Nano-X-Imaging-Ltd.-Class-Action-Lawsuit 2026-06-13T01:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T01:00:00.000Z Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit NNOX https://mms.businesswire.com/media/20260612279863/en/805853/21/Robbins_LLP.jpg https://www.businesswire.com/news/home/20260612170816/de 2026-06-13T00:45:00.000Z weekly 0.5 Business Wire de PressRelease 2026-06-13T00:45:00.000Z Das grundlegende hämatologische Produktportfolio von BeOne Medicines läutet auf der EHA 2026 eine neue Ära der Innovation bei B-Zell-Krebserkrankungen ein 688235,06160,ONC https://mms.businesswire.com/media/20260612170816/de/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260612866953/fr 2026-06-13T00:39:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-06-13T00:39:00.000Z IQM nomme Barbara Venneman, membre du conseil d’administration de Vanguard et ancienne directrice mondiale de Deloitte Digital, au sein de son conseil d’administration RAAQ https://mms.businesswire.com/media/20260612866953/fr/2830401/21/IQM-Barbara-Venneman-PR.jpg https://www.businesswire.com/news/home/20260612303493/en/GeneDx-Holdings-Corp.-WGS-Investors-August-3-2026-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-Contact-Kessler-Topaz-Meltzer-Check-LLP 2026-06-13T00:39:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T00:39:00.000Z GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP WGS https://mms.businesswire.com/media/20260612303493/en/2830824/21/KTMC_Icon.jpg https://www.businesswire.com/news/home/20260612822668/es 2026-06-13T00:36:00.000Z weekly 0.5 Business Wire es PressRelease 2026-06-13T00:36:00.000Z La línea de productos de hematología de BeOne Medicines marca el rumbo de la próxima era de innovación en el cáncer de células B en la EHA 2026 688235,06160,ONC https://mms.businesswire.com/media/20260612822668/es/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260612276693/en/VIA-INVESTOR-NOTICE-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-Via-Transportation-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit 2026-06-13T00:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T00:30:00.000Z VIA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Via Transportation, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit VIA https://mms.businesswire.com/media/20260612276693/en/2313484/21/RGRD_Logo_2v2.jpg https://www.businesswire.com/news/home/20260612644964/es 2026-06-13T00:25:00.000Z weekly 0.5 Business Wire es PressRelease 2026-06-13T00:25:00.000Z Charlotte Tilbury, condecorada con la distinción de CBE en la lista de honores del cumpleaños del Rey de 2026 https://mms.businesswire.com/media/20260612644964/es/2830618/21/Charlotte_Tilbury_CBE.jpg https://www.businesswire.com/news/home/20260612139157/en/ADMA-INVESTOR-ALERT-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-ADMA-Biologics-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit 2026-06-13T00:15:00.000Z weekly 0.5 Business Wire en PressRelease 2026-06-13T00:15:00.000Z ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ADMA https://mms.businesswire.com/media/20260612139157/en/2313484/21/RGRD_Logo_2v2.jpg